OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues (PR Newswire)

UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company, announced a granted US patent on Oxalobacter formigenes secretagogues. OxThera AB, a spinout of Ixion, is a UF Innovate | Sid Martin Biotech alumnus.

Oxabact®, a formulation of highly concentrated lyophilized Oxalobacter formigenes, is being developed by OxThera AB as a potential treatment for patients with primary hyperoxaluria (PH). Oxabact® is designed to increase the intestinal secretion of oxalate from plasma and thereby decrease and prevent oxalate crystal accumulation and kidney deterioration. Oxalobacter formigenes produces specific secretagogues that enhance active transepithelial transport of oxalate from the bloodstream and into the intestines. OxThera isolated and defined such secretagogues, patent number US 10,125,176, and are now exploring the potential to use these therapeutically.

Learn more about OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues.